PL4272735T3 - Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek - Google Patents

Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek

Info

Publication number
PL4272735T3
PL4272735T3 PL23198295.0T PL23198295T PL4272735T3 PL 4272735 T3 PL4272735 T3 PL 4272735T3 PL 23198295 T PL23198295 T PL 23198295T PL 4272735 T3 PL4272735 T3 PL 4272735T3
Authority
PL
Poland
Prior art keywords
tablets
immediate
drug
processes
forming
Prior art date
Application number
PL23198295.0T
Other languages
English (en)
Inventor
Sanjeev Kothari
Piscilla MANTIK
Alexander MAUERER
Hamid REZAEI
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of PL4272735T3 publication Critical patent/PL4272735T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL23198295.0T 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek PL4272735T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562186556P 2015-06-30 2015-06-30

Publications (1)

Publication Number Publication Date
PL4272735T3 true PL4272735T3 (pl) 2025-10-06

Family

ID=56373188

Family Applications (3)

Application Number Title Priority Date Filing Date
PL16736730T PL3316867T3 (pl) 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
PL21160939.1T PL3881833T3 (pl) 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
PL23198295.0T PL4272735T3 (pl) 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL16736730T PL3316867T3 (pl) 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
PL21160939.1T PL3881833T3 (pl) 2015-06-30 2016-06-29 Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek

Country Status (17)

Country Link
US (3) US10478400B2 (pl)
EP (3) EP3316867B1 (pl)
JP (3) JP6914202B2 (pl)
KR (2) KR102881659B1 (pl)
CN (2) CN108135854B (pl)
AR (2) AR105184A1 (pl)
AU (2) AU2016287422B2 (pl)
BR (1) BR112017028218A2 (pl)
CA (1) CA2987912C (pl)
ES (3) ES2969014T3 (pl)
HR (2) HRP20240045T1 (pl)
IL (2) IL256299B2 (pl)
MX (3) MX377955B (pl)
PL (3) PL3316867T3 (pl)
SI (2) SI3316867T1 (pl)
TW (3) TWI804919B (pl)
WO (1) WO2017004122A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL256299B2 (en) * 2015-06-30 2023-11-01 Genentech Inc Immediate-release tablets containing a drug and processes for creating the tablets
US10751288B2 (en) * 2016-08-23 2020-08-25 New Jersey Institute Of Technology Dry processed surface coated engineering excipients
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
WO2019073331A2 (en) * 2017-10-13 2019-04-18 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITIONS OF APREMILAST
CN110151763A (zh) * 2019-06-26 2019-08-23 深圳市第三人民医院 考比替尼作为制备治疗结核病药物中的应用
GB201913972D0 (en) 2019-09-27 2019-11-13 Univ Ulster Pharmaceutical Delivery Device and method of manufacture
BR112022024533A2 (pt) * 2020-06-19 2022-12-27 Glaxosmithkline Ip No 2 Ltd Formulação compreendendo daprodustat
JPWO2023145486A1 (pl) * 2022-01-28 2023-08-03
TW202400135A (zh) * 2022-03-07 2024-01-01 美商健生醫藥公司 包含阿替卡普蘭之組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
CA2614468A1 (en) * 2005-07-15 2007-01-25 Teva Pharmaceutical Industries Ltd. Novel granulation process and granulate produced therefrom
US8146000B1 (en) 2005-10-07 2012-03-27 Goodwell Technologies, Inc. Integrated transactional workflows distributed across multiple contact centers
CN103524392B (zh) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
WO2009120844A2 (en) * 2008-03-26 2009-10-01 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
CN102238941A (zh) * 2008-09-17 2011-11-09 迈兰实验室公司 颗粒、制备它们的方法和包含它们的药物产品
KR101429331B1 (ko) * 2009-06-22 2014-08-11 와이어쓰 엘엘씨 이부프로펜 나트륨 정제 및 이부프로펜 나트륨을 포함하는 제약 조성물의 제조 방법
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
MX2013014151A (es) * 2011-06-03 2014-01-23 Hoffmann La Roche Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k.
WO2013082511A1 (en) * 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
HUE050327T2 (hu) * 2011-12-27 2020-11-30 Amgen Europe Gmbh Készítmények (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metánszulfonil-etil]-4-acetilaminoizoindolin-1,3-dion tartalommal
KR101915942B1 (ko) * 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
JP6335169B2 (ja) * 2012-08-17 2018-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法
HRP20180670T1 (hr) 2012-10-12 2018-07-13 Exelixis Inc. Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
MX370175B (es) * 2013-03-06 2019-12-04 Novartis Ag Formulaciones de compuestos orgánicos.
DK3019166T3 (da) * 2013-07-12 2019-07-29 Piramal Entpr Ltd A Pharmaceutical Combination for the Treatment of Melanoma
SG11201600378SA (en) * 2013-07-30 2016-02-26 Gilead Connecticut Inc Formulation of syk inhibitors
EP3083640A1 (en) * 2013-12-16 2016-10-26 F. Hoffmann-La Roche AG Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
IL256299B2 (en) 2015-06-30 2023-11-01 Genentech Inc Immediate-release tablets containing a drug and processes for creating the tablets
AR105483A1 (es) * 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
PL3316867T3 (pl) 2021-10-11
CA2987912C (en) 2023-01-24
MX2017016163A (es) 2018-08-15
CN108135854B (zh) 2022-03-11
JP7232284B2 (ja) 2023-03-02
MX2022015606A (es) 2023-02-01
KR102881659B1 (ko) 2025-11-06
MX2020013162A (es) 2021-02-18
TW202337463A (zh) 2023-10-01
JP2018519305A (ja) 2018-07-19
SI3316867T1 (sl) 2021-08-31
ES3036390T3 (en) 2025-09-18
EP4272735A1 (en) 2023-11-08
CN108135854A (zh) 2018-06-08
EP3316867B1 (en) 2021-03-10
ES2871175T3 (es) 2021-10-28
ES2969014T3 (es) 2024-05-16
PL3881833T3 (pl) 2024-05-13
EP4272735C0 (en) 2025-06-18
JP2021138716A (ja) 2021-09-16
SI3881833T1 (sl) 2024-03-29
EP3316867A1 (en) 2018-05-09
WO2017004122A1 (en) 2017-01-05
AU2016287422B2 (en) 2021-11-18
TWI804919B (zh) 2023-06-11
EP4272735B1 (en) 2025-06-18
US20220339111A1 (en) 2022-10-27
BR112017028218A2 (pt) 2018-08-28
MX377955B (es) 2025-03-10
AR121624A2 (es) 2022-06-22
IL303352B2 (en) 2025-10-01
CN114177157B (zh) 2024-08-02
US20180116966A1 (en) 2018-05-03
US10478400B2 (en) 2019-11-19
JP2023071769A (ja) 2023-05-23
HRP20210828T1 (hr) 2021-07-09
JP6914202B2 (ja) 2021-08-04
KR20180021814A (ko) 2018-03-05
EP3881833B1 (en) 2023-11-01
TWI795344B (zh) 2023-03-11
AU2016287422A1 (en) 2018-01-04
HK1254389A1 (zh) 2019-07-19
AU2022201067A1 (en) 2022-03-10
TW202206068A (zh) 2022-02-16
KR20240152414A (ko) 2024-10-21
IL256299B1 (en) 2023-07-01
IL256299B2 (en) 2023-11-01
KR102716253B1 (ko) 2024-10-11
HRP20240045T1 (hr) 2024-03-29
CA2987912A1 (en) 2017-01-05
AR105184A1 (es) 2017-09-13
IL256299A (en) 2018-02-28
US20200085749A1 (en) 2020-03-19
CN114177157A (zh) 2022-03-15
IL303352B1 (en) 2025-06-01
JP7607062B2 (ja) 2024-12-26
IL303352A (en) 2023-08-01
TW201705944A (zh) 2017-02-16
EP3881833A1 (en) 2021-09-22
TWI872459B (zh) 2025-02-11

Similar Documents

Publication Publication Date Title
IL256299A (en) Immediate-release tablets containing drug and processes for creating the tablets
SG11202002528SA (en) Radioactive drug
ZAA201800549S (en) Tablets
EP3638658C0 (en) PHARMACEUTICAL COMPOUNDS
GB201704714D0 (en) Pharmaceutical compounds
GB2543579B (en) Pivoting tablet die
GB201704965D0 (en) Pharmaceutical compounds
GB201703881D0 (en) Pharmaceutical compounds
SI3340968T1 (sl) Implantabilne tablete naltreksona
GB201601865D0 (en) Oral dosage products and processes
AU201712967S (en) Pill packaging
GB201819094D0 (en) Tablet dispenser
IL273704A (en) Pharmaceutical bilayer tablet formulations
GB201704966D0 (en) Pharmaceutical compounds
HUE048566T2 (hu) Gyógyszercsomagolás
HUE041260T2 (hu) Gyógyszertabletták bevonására szolgáló készülék
PT3646864T (pt) Medicamento contendo pemafibrato
PL3768248T3 (pl) Stała tabletka farmaceutyczna
ZA201707549B (en) Extended release tablet comprising a weight-loss drug
PH32017000907S1 (en) Pharmaceutical tablets
AP00976S1 (en) Pharmaceutical tablets
AP00975S1 (en) Pharmaceutical tablets
AP00977S1 (en) Pharmaceutical tablets
EM43669380001S (pl) Tabletki
ZA201806493B (en) Insecticidal tablet